Business Wire

Slate Asset Management Appoints Bozena Jankowska as Managing Director and Global Head of ESG

23.11.2021 11:00:00 EET | Business Wire | Press release

Share

Slate Asset Management ("Slate" or “the firm”), a global alternative investment platform focused on real estate, today announced that it has appointed Bozena Jankowska as Managing Director and Global Head of Environmental, Social and Governance (“ESG”), based in Slate’s London office.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211123005469/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Bozena Jankowska, Managing Director and Global Head of ESG at Slate Asset Management (Photo: Business Wire)

Jankowska has nearly two decades of experience at the intersection of finance and corporate responsibility. She will lead the development of best-in-class ESG practices and policies aimed at safeguarding the long-term performance of Slate’s global investments. Additionally, Jankowska will oversee and advance Slate’s corporate social responsibility strategy and the integration of ESG into Slate’s investment and asset management processes, as well as stakeholder communications and reporting. Her focus over the next year will be to complete an ESG assessment of Slate’s assets under management, with an initial focus on Europe, before subsequently expanding to the entirety of Slate’s global platform.

“We are very pleased to welcome Bozena to our team,” said Brady Welch, Founding Partner at Slate. “From the outset, Bozena’s commitment to innovation and her entrepreneurial spirit set her apart from other candidates. She led the drive for sustainability in the finance industry well before it became mainstream, and her deep-rooted technical knowledge of complex global sustainability topics will be extremely valuable as we continue driving our ESG strategy forward.”

Blair Welch, Founding Partner at Slate Asset Management, added: “We understand that having sound ESG practices underpinning our approach to investment and asset management benefits our tenants, our communities and our investors. Bozena’s appointment displays our deep commitment to embedding ESG principles across our business.”

Jankowska was Global Co-Head of ESG at Allianz Global Investors (“AGI”), responsible for ESG integration across the firm’s investment portfolio. During her 15-year tenure at AGI, she pioneered a number of innovative ESG strategies and processes, establishing a global ESG team and growing AGI’s total sustainable investment assets under management from €70 million to over €30 billion. She also designed, managed and marketed the Allianz Global Investors clean technology fund – Global Ecotrends – which grew from $10 million in seed funding to $1 billion in assets under management, becoming a global franchise for the firm.

After leaving AGI, Jankowska founded a successful women’s sustainable fashion label, overseeing the brand’s business strategy and creative direction, including sustainable materials research and sourcing, supply chain management, and successful partnerships with non-governmental organizations focused on environmental sustainability.

“I am excited to join an organization that clearly understands how best-in-class ESG practices can play a critical role in long-term value creation,” said Jankowska. “I look forward to working with the team at Slate to continue raising the bar on the firm’s ESG performance and identifying new and innovative ways to add further rigor to our ESG approach.”

Jankowska holds a Bachelor of Science in Environmental Science from the University of Sussex. She completed her Master of Science in Environment Technology with distinction at Imperial College.

Jankowska joined Slate on November 22.

About Slate Asset Management
Slate Asset Management is a global alternative investment platform focused on real estate. We focus on fundamentals with the objective of creating long-term value for our investors and partners. Slate’s platform has a range of investment strategies, including opportunistic, value add, core plus and debt investments. We are supported by exceptional people and flexible capital, which enable us to originate and execute on a wide range of compelling investment opportunities. Visit slateam.com to learn more.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Slate Asset Management
Karolina Kmiecik
Karolina@slateam.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye